The Profile of Prostate Epithelial Cytokines and Its Impact on Sera Prostate Specific Antigen Levels

Overview

Journal Inflammation

Specialties Allergy & Immunology
Pathology

Date 2009 Apr 29

PMID 19399601

Citations 16

Authors

Yosra Bouraoui Mechergui

Awatef Ben Jemaa

Chekib Mezigh

Benito Fraile

Nawfel Ben Rais

Ricardo Paniagua

Mar Royuela

Ridha Oueslati

Affiliations

Soon will be listed here.

Abstract

The aim of this study was determined the expression of pro inflammatory cytokines in prostate epithelial cells. Furthermore, we analysed the relation between these cytokines and sera PSA levels according the three groups: 0-4, 4-20 and >20 ng/mL. The study was carried out in five normal prostate (NP), 27 benign prostate hyperplastic (BPH) and 18 prostate cancer (PC). Immunohistochemical and Western blot analysis was performed. Serum levels of PSA were assayed by Immulite autoanalyser. The western Blotting analysis revealed an immunoexpression of IL-1alpha, IL-6 and TNFalpha in BPH and PC. IL-1alpha, was absent in NP. Immunohistochemical analysis showed significant high optical density to IL-1alpha and IL-6 in cancer epithelial cells (19.45 +/- 3.25 and 26.2 +/- 3.19) compared to normal cells (1.73 +/- 1.51 and 4.83 +/- 2.65). While, TNFalpha optical densities were not significant in NP (12.03 +/- 2.9), BPH (9.87 +/- 3.85) and PC (13.34 +/- 2.34). The different profiles of cytokines according sera PSA levels showed a high immunoexpression of the profile (IL-6+, IL-1alpha+) in BPH patients with PSA between 0-4 and 4-20 ng/mL. However, PC patients with sera PSA between 4 and 20 ng/mL, showed a significant high immunoexpression of the profile (IL-6+, IL-1alpha-). This data demonstrate a locally production of pro-inflammatory cytokines by prostate epithelial cells and a cross talk between PSA and these cytokines in prostate pathologies.

Citing Articles

Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives.

Kaltsas A, Giannakas T, Stavropoulos M, Kratiras Z, Chrisofos M Diseases. 2025; 13(2).

PMID: 39997060 PMC: 11854834. DOI: 10.3390/diseases13020053.

Extract Alleviates Progression of Benign Prostatic Hyperplasia via Modification of Proliferation, Apoptosis, and Inflammation.

Baek E, Hwang Y, Hong E, Won Y, Kwun H Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204137 PMC: 11357589. DOI: 10.3390/ph17081032.

Immune Regulation of Seminal Plasma on the Endometrial Microenvironment: Physiological and Pathological Conditions.

Shen Q, Wu X, Chen J, He C, Wang Z, Zhou B Int J Mol Sci. 2023; 24(19).

PMID: 37834087 PMC: 10572377. DOI: 10.3390/ijms241914639.

Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo.

Baek E, Hwang Y, Park S, Hong E, Won Y, Kwun H Res Rep Urol. 2022; 14:313-326.

PMID: 36187165 PMC: 9519014. DOI: 10.2147/RRU.S381713.

Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer.

Xu H, Chen Y, Gu M, Liu C, Chen Q, Zhan M Metabolites. 2021; 11(11).

PMID: 34822423 PMC: 8618281. DOI: 10.3390/metabo11110765.

References

Dinarello C . Proinflammatory cytokines. Chest. 2000; 118(2):503-8. DOI: 10.1378/chest.118.2.503. View

Yan L, Anderson G, DeWitte M, Nakada M . Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer. 2006; 42(6):793-802. DOI: 10.1016/j.ejca.2006.01.013. View

Trapman J, Cleutjens K . Androgen-regulated gene expression in prostate cancer. Semin Cancer Biol. 1997; 8(1):29-36. DOI: 10.1006/scbi.1997.0050. View

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542-7. DOI: 10.1001/jama.279.19.1542. View

Luderer A, Chen Y, Soriano T, Kramp W, Carlson G, Cuny C . Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 1995; 46(2):187-94. DOI: 10.1016/s0090-4295(99)80192-7. View

Cardone M, Roy N, Stennicke H, Salvesen G, Franke T, Stanbridge E . Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998; 282(5392):1318-21. DOI: 10.1126/science.282.5392.1318. View

Isaacs J . The biology of hormone refractory prostate cancer. Why does it develop?. Urol Clin North Am. 1999; 26(2):263-73. DOI: 10.1016/s0094-0143(05)70066-5. View

Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H . Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000; 6(7):2702-6. View

Panja A, Goldberg S, Eckmann L, Krishen P, Mayer L . The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. J Immunol. 1998; 161(7):3675-84. View

10.

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

11.

de Visser K, Eichten A, Coussens L . Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006; 6(1):24-37. DOI: 10.1038/nrc1782. View

12.

Michalaki V, Syrigos K, Charles P, Waxman J . Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004; 90(12):2312-6. PMC: 2409519. DOI: 10.1038/sj.bjc.6601814. View

13.

Bouraoui Y, Ricote M, Garcia-Tunon I, Rodriguez-Berriguete G, Touffehi M, Ben Rais N . Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. Cancer Detect Prev. 2008; 32(1):23-32. DOI: 10.1016/j.cdp.2008.02.007. View

14.

Lilja H . Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol. 1993; 11(4):188-91. DOI: 10.1007/BF00185066. View

15.

Castro P, Giri D, Lamb D, Ittmann M . Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate. 2003; 55(1):30-8. DOI: 10.1002/pros.10204. View

16.

Balk S, Ko Y, Bubley G . Biology of prostate-specific antigen. J Clin Oncol. 2003; 21(2):383-91. DOI: 10.1200/JCO.2003.02.083. View

17.

Ricote M, Garcia-Tunon I, Bethencourt F, Fraile B, Paniagua R, Royuela M . Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer. 2004; 100(7):1388-96. DOI: 10.1002/cncr.20142. View

18.

Ishihara K, Hirano T . IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002; 13(4-5):357-68. DOI: 10.1016/s1359-6101(02)00027-8. View

19.

Brunet A, Bonni A, Zigmond M, Lin M, Juo P, Hu L . Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96(6):857-68. DOI: 10.1016/s0092-8674(00)80595-4. View

20.

Lee S, Lou W, Nadiminty N, Lin X, Gao A . Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate. 2005; 64(2):160-7. DOI: 10.1002/pros.20218. View